Rapid and preemptive evaluation of individual anti-hepatitis C virus treatment outcome capability by a short-term autologous liver tissue culture system

New Microbiologica

Volumn 37, Issue 3, 2014, Pages 363-367

  Cimini, Eleonora ^a   Bordoni, Veronica ^a   Lalle, Eleonora ^b   Montalbano, Marzia ^c   Visco Comandini, Ubaldo ^c   Taibi, Chiara ^c   D'Offizi, Gianpiero ^c   Lionetti, Raffaella ^c   Scognamiglio, Paola ^a   Capobianchi, Maria Rosaria ^b   Martini, Federico ^a   Agrati, Chiara ^a,b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Virology Laboratory   (Italy)

^c Clinical Department   (Italy)

Author keywords

HCV standard therapy; In vitro HCV replication; In vitro tissue model; Liver biopsies

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; BIOPSY; DRUG EFFECT; DRUG MONITORING; EVALUATION STUDY; FEMALE; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; ISOLATION AND PURIFICATION; LIVER; MALE; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; DRUG MONITORING; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84906489507     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. ABE H., HAYES C.N., HIRAGA N., IMAMURA M., TSUGE M., MIKI D., ET AL. (2013). A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis c using ultra-deep sequencing. Am. J. Gastroenterol. 108, 1464-1472.
2. ARNAUD C., TRéPO C., PETIT M.A. (2013). Predictors of the therapeutic response inhepatitis C. A 2013 update. Clinics and Research in Hepatology and Gastroenterology.
3. CHANG M.L., SUNG K.F., SHEEN I.S., LIN S.M., YEH C.T. (2009). A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C. J. Viral. Hepat. 16, 359-366.
4. COLOMBO M., ZEUZEM S. (2013). Pratical insights into enhanced management of patients with HCV infection with direct antiviral agents. Digestive and Liver Disease. 45, S313.
5. DANIEL H.D., DAVID J., GRANT P.R, GARSON J.A., CHANDY G.M., ABRAHAM P. (2008). Whole blood as an alternative to plasma for detection of hepatitis C virus RNA. J. Clin. Microbiol. 46, 3791-3794.
6. HAYASHI N., TAKEHARA T. (2006). Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol. 41, 17-27.
7. HOOFNAGLE J.H. (2002). Course and outcome of hepatitis C. Hepatology. 36, S21-29.
8. KANWAL F., HOANG T., KRAMER J.R., ASCH S.M., GOETZ M.B., ZERINGUE A., ET AL. (2011). Increasing prevalence of HCC and cirrhosis in patientswith chronic hepatitis C virus infection. Gastroenterology. 140, 1182-1188.
9. LAWITZ E., LALEZARI J.P., HASSANEIN T., KOWDLEY K.V., POORDAD F.F., SHEIKH A.M., ET AL. (2013). Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect. Dis. 13, 401-408.
10. MANNS M.P., MCHUTCHISON J.G., GORDON S.C., RUSTGI V.K., SHIFFMAN M., REINDOLLAR R., ET AL. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358, 958-965.
11. MORIISHI K., MATSUURA Y. (2007). Evaluation systems for anti-HCV drugs. Adv. Drug. Deliv. Rev. 59, 1213-1121.
12. YEH C.T., HWANG D.R., LAI H.Y., HSU J.T. (2003). Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. Biochem. Biophys. Res. Commun. 310, 537-541.
13. ZEUZEM S., ANDREONE P., POL S., LAWITZ E., DIAGO M., ROBERTS S., ET AL. (2011). Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428.